TYMS and rheumatoid arthritis: Since TS levels were found to be predictive of MTX therapeutic outcome [13], [14] and genetic polymorphisms in TS gene (TYMS) have been associated with TS levels [15], [16], pharmacogenomics has raised great interest and, in fact, some studies have attempted to clarify the influence of genetic variations on clinical response to MTX in RA [17].